Fig. 4

p53 inhibition does not affect cisplatin sensitivity but is required for the enhanced cell death observed in the combination treatment. a SiHa cells were transfected with siRNA for 48 h and p53 knock-down confirmed via western blot. GAPDH was included as a loading control. The full-length blots are shown in Supplementary Fig. 4A. b MTT assay showing that p53 knock-down does not affect cell viability after 48-h cisplatin treatment. Data shown are the mean ± SEM of experiments performed in triplicate and repeated two independent times. c Western blot showing that p53 knock-down does not affect cisplatin-induced PARP cleavage in SiHa cells. GAPDH was included as loading control, and densitometrical quantification is presented. Results shown are representative of experiments performed three times. The full-length blots are shown in Supplementary Fig. 4B. d MTT assay comparing cell viability between single cisplatin treatment and INI-43-cisplatin combination treatment, in p53 knock-down SiHa cells. To compare the degree of enhancement of cell death as a result of the combination treatment, cell viability was normalized to cells receiving single cisplatin treatment. Results shown are mean ± SEM of experiments performed in triplicate and repeated two independent times (*p < 0.05). e Western blot showing that p53 knock-down abrogated the enhancement of PARP cleavage observed after combination treatment compared to single cisplatin treatment. GAPDH was included as the loading control, and densitometrical quantification is shown. The full-length blots are shown in Supplementary Fig. 4C. Results shown are representative of three independent experiments